Acurx Pharmaceuticals, Inc. ACXP shares are trading higher Wednesday, though the stock remains down more than 30% over the last month.
What To Know:
Acurx Pharmaceuticals stock is continuing a volatile trend from last week, though the company last released news at the beginning of October.
On Oct. 2, Acurx announced positive results from a Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for the treatment of patients with Clostridioides difficile infection.
Shares of ACXP are moving higher on heavy trading volume Wednesday. According to data from Benzinga Pro, more than 1.4 million shares have already been traded in the session, far exceeding the stock's 100-day average of less than 544 thousand shares.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Related News: What's Going On With Nikola Corporation Stock Today?
ACXP Price Action: According to Benzinga Pro, Acurx Pharmaceuticals shares are up 20% at $6.11 at the time of publication.
Image: Mahmoud Ahmed from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
